Status:
COMPLETED
A Registry for Patients Treated on the Clinical Trial TAX 3503
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Laval University
Vancouver General Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this study is to continue follow-up on patients who were treated on the study called TAX 3505 (MSK IRB #07-101). The sponsor of this study, has decided to end the study early, before al...
Eligibility Criteria
Inclusion
- The registry will include the database of all patients registered to TAX3503. Those patients who will be prospectively tracked through the registry are those who meet the following criteria:
- The patient must have been registered to TAX3503
- The patient must not have met the definition of progression as defined in TAX3503 while on TAX3503 Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
Exclusion
- Patients who were not registered to TAX3503 are not eligible to have their data stored in this registry.
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 4 2022
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT01813370
Start Date
March 1 2013
End Date
March 4 2022
Last Update
March 8 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
John Hopkins Medical Center
Baltimore, Maryland, United States, 21287
2
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
3
Duke University Medical Center
Durham, North Carolina, United States, 27701
4
Urological Associates of Lancaster
Lancaster, Pennsylvania, United States, 17601